Dupixent set for ninth US approval after Phase III AFRS success
Patients treated with Dupixent were 92% less likely to need corticosteroids or surgery.
10 November 2025
10 November 2025
Patients treated with Dupixent were 92% less likely to need corticosteroids or surgery.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.